Clinical Trial Update: Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-negative breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Progesterone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Decitabine (Dacogen) (decitabine)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-09